Seer (SEER) Expected to Announce Earnings on Thursday

Seer (NASDAQ:SEER) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $4.60 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Seer Price Performance

SEER stock opened at $2.02 on Thursday. The company has a market capitalization of $112.70 million, a P/E ratio of -1.49 and a beta of 1.63. Seer has a 12 month low of $1.62 and a 12 month high of $2.41. The firm’s fifty day simple moving average is $1.87 and its 200-day simple moving average is $2.02.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SEER. Wall Street Zen raised shares of Seer to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Seer

A number of hedge funds have recently bought and sold shares of SEER. Occudo Quantitative Strategies LP purchased a new stake in shares of Seer in the second quarter valued at about $25,000. Marshall Wace LLP purchased a new position in Seer during the fourth quarter worth about $85,000. Quadrature Capital Ltd acquired a new position in Seer in the 4th quarter valued at about $101,000. Barclays PLC grew its stake in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares during the period. Finally, Corient Private Wealth LLC increased its holdings in shares of Seer by 46.3% during the 2nd quarter. Corient Private Wealth LLC now owns 63,200 shares of the company’s stock worth $135,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 75.20% of the company’s stock.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.